Search

Your search keyword '"Donahue A"' showing total 219 results

Search Constraints

Start Over You searched for: Author "Donahue A" Remove constraint Author: "Donahue A" Journal journal of urology Remove constraint Journal: journal of urology
219 results on '"Donahue A"'

Search Results

1. Randomized Trial of Transverse vs Vertical Extraction Site Incision After Robotic Radical Prostatectomy.

3. MP16-17 PHASE I STUDY OF INTRAVESICAL FC-OPTIMIZED ANTI-CD40 AGONIST ANTIBODY 2141-V11 FOR NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN (BCG)

4. MP25-19 RESULTS OF THE PCM-204 PHASE 2B TRIAL OF PARTIAL-GLAND ABLATION FOR MEN WITH INTERMEDIATE-RISK PROSTATE CANCER WITH PADELIPORFIN (WST11 OR TOOKAD) VASCULAR-TARGETED PHOTODYNAMIC THERAPY

5. PD34-08 A PROSPECTIVE RANDOMIZED PHASE 3 TRIAL EVALUATING BENEFITS OF PERISTOMAL MESH PLACEMENT AT THE TIME OF RADICAL CYSTECTOMY AND ILEAL CONDUIT FORMATION

6. PD14-07 ERCC2 ALTERATIONS ARE ASSOCIATED WITH ENHANCED SENSITIVITY TO INTRAVESICAL BACILLUS CALMETTE-GUÉRIN IN HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER

7. PD22-12 A PHASE-1 TRIAL OF REAL-TIME INTRAOPERATIVE FLUORESCENT IMAGING OF NERVE STRUCTURES USING ILLUMINARE-1, A NOVEL MYELIN BINDING FLUOROPHORE

8. Association of Biochemically Verified Post-Diagnosis Smoking and Nonmuscle-Invasive Bladder Cancer Recurrence Risk

9. LBA02-04 OUTCOMES AND GENOMIC CHARACTERISTICS OF NEWLY DIAGNOSED HIGH GRADE TA PAPILLARY UROTHELIAL CARCINOMA TREATED WITH INTRAVESICAL CHEMOTHERAPY VS BACILLUS CALMETTE GUERIN (BCG): A COMPARATIVE STUDY DURING THE BCG SHORTAGE

10. MP63-13 TRIALS IN PROGRESS: A PHASE I/II TRIAL OF INTRAVESICAL CHEMOIMMUNOTHERAPY WITH GEMCITABINE AND BACILLUS CALMETTE-GUÉRIN (BCG) FOR PATIENTS WITH BCG-EXPOSED HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)

11. MP63-08 CLINICAL AND GENOMIC RISK FEATURES OF HIGH GRADE T1 NON-MUSCLE INVASIVE BLADDER CANCER

12. PD09-07 ASSESSING THE UTILITY OF A CELL-FREE TUMOR (ct)DNA ASSAY (MSK-ACCESS) IN NODE POSITIVE (N+) MUSCLE INVASIVE BLADDER CANCER (MIBC) PATIENTS (pts) UNDERGOING NEOADJUVANT CHEMOTHERAPY (NAC)

13. PD36-08 PERIOPERATIVE OUTCOMES OF RADICAL CYSTECTOMY FOLLOWING NEOADJUVANT GEMCITABINE, CISPLATIN AND ATEZOLIZUMAB

14. MP63-13 TRIALS IN PROGRESS: A PHASE I/II TRIAL OF INTRAVESICAL CHEMOIMMUNOTHERAPY WITH GEMCITABINE AND BACILLUS CALMETTE-GUÉRIN (BCG) FOR PATIENTS WITH BCG-EXPOSED HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)

15. PD09-07 ASSESSING THE UTILITY OF A CELL-FREE TUMOR (ct)DNA ASSAY (MSK-ACCESS) IN NODE POSITIVE (N+) MUSCLE INVASIVE BLADDER CANCER (MIBC) PATIENTS (pts) UNDERGOING NEOADJUVANT CHEMOTHERAPY (NAC)

17. PD36-08 PERIOPERATIVE OUTCOMES OF RADICAL CYSTECTOMY FOLLOWING NEOADJUVANT GEMCITABINE, CISPLATIN AND ATEZOLIZUMAB

18. LBA02-04 OUTCOMES AND GENOMIC CHARACTERISTICS OF NEWLY DIAGNOSED HIGH GRADE TA PAPILLARY UROTHELIAL CARCINOMA TREATED WITH INTRAVESICAL CHEMOTHERAPY VS BACILLUS CALMETTE GUERIN (BCG): A COMPARATIVE STUDY DURING THE BCG SHORTAGE

19. The Duration of Antibiotics Prophylaxis at the Time of Catheter Removal after Radical Prostatectomy: Clinically Integrated, Cluster, Randomized Trial

20. Examining the Accuracy of Self-Reported Smoking-Related Exposure among Recently Diagnosed Nonmuscle Invasive Bladder Cancer Patients

21. MP41-20 DEFINING THE UTILITY OF MSK-ACCESS, A CELL-FREE TUMOR DNA ASSAY, IN PATIENTS TREATED WITH RADICAL CYSTECTOMY FOR MUSCLE-INVASIVE BLADDER CANCER

22. Late Recurrences Following Radical Cystectomy Have Distinct Prognostic and Management Considerations

23. Utility of Routine Preoperative 18 F-Fluorodeoxyglucose Positron Emission Tomography/Computerized Tomography in Identifying Pathological Lymph Node Metastases at Radical Cystectomy

27. MP54-01 DISCORDANCE BETWEEN CLINICAL AND PATHOLOGIC CARCINOMA IN SITU FOR TURBT AND RADICAL CYSTECTOMY IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER: IMPLICATIONS FOR BCG UNRESPONSIVE CLINICAL TRIAL DESIGN AND INTERPRETATION

29. MP41-20 DEFINING THE UTILITY OF MSK-ACCESS, A CELL-FREE TUMOR DNA ASSAY, IN PATIENTS TREATED WITH RADICAL CYSTECTOMY FOR MUSCLE-INVASIVE BLADDER CANCER

30. MP19-19 PREDICTING PROFICIENCY DURING ROBOTIC PROSTATECTOMY OF UROLOGY TRAINEES USING A NOVEL, SYSTEMIC SURGICAL TRAINING PROGRAM

32. MP01-20 A RANDOMIZED CONTROLLED TRIAL FOR OPIOID-LIMITING PAIN CONTROL AFTER TRANSURETHRAL RESECTION OF THE PROSTATE: MULTIMODAL PAIN REGIMEN WITH EDUCATIONAL INTERVENTION VERSUS STANDARD OF CARE

34. MP54-01 DISCORDANCE BETWEEN CLINICAL AND PATHOLOGIC CARCINOMA IN SITU FOR TURBT AND RADICAL CYSTECTOMY IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER: IMPLICATIONS FOR BCG UNRESPONSIVE CLINICAL TRIAL DESIGN AND INTERPRETATION

35. PD43-07 CLINICAL CHARACTERISTICS ASSOCIATED WITH HIGH-RISK CANCER-PREDISPOSITION GERMLINE MUTATIONS IN PATIENTS WITH UROTHELIAL CARCINOMA: IMPLICATIONS FOR GENETIC TESTING

36. MP46-04 RESULTS OF THE PCM-204 PHASE 2B TRIAL OF PARTIAL-GLAND ABLATION FOR MEN WITH INTERMEDIATE-RISK PROSTATE CANCER WITH PADELIPORFIN (WST11 OR TOOKAD) VASCULAR-TARGETED PHOTODYNAMIC THERAPY

37. MP16-08 RE-EVALUATION OF INTRAVESICAL GEMCITABINE IN BACILLUS CALMETTE-GUERIN UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER

38. MP16-08 RE-EVALUATION OF INTRAVESICAL GEMCITABINE IN BACILLUS CALMETTE-GUERIN UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER

40. PD43-07 CLINICAL CHARACTERISTICS ASSOCIATED WITH HIGH-RISK CANCER-PREDISPOSITION GERMLINE MUTATIONS IN PATIENTS WITH UROTHELIAL CARCINOMA: IMPLICATIONS FOR GENETIC TESTING

41. MP46-04 RESULTS OF THE PCM-204 PHASE 2B TRIAL OF PARTIAL-GLAND ABLATION FOR MEN WITH INTERMEDIATE-RISK PROSTATE CANCER WITH PADELIPORFIN (WST11 OR TOOKAD) VASCULAR-TARGETED PHOTODYNAMIC THERAPY

42. Utility of Routine Preoperative 18 F-Fluorodeoxyglucose Positron Emission Tomography/Computerized Tomography in Identifying Pathological Lymph Node Metastases at Radical Cystectomy. Reply.

43. PD47-02 'ACTIONABLE' GENOMIC ALTERATIONS IN CHEMOTHERAPY RESISTANT MUSCLE-INVASIVE BLADDER CANCER

44. MP30-14 MAJORITY OF ONABOTULINUMTOXINA-NAIVE PATIENTS WITH IDIOPATHIC OVERACTIVE BLADDER DO NOT REPEAT CHEMODENERVATION: FACTORS AFFECTING PATIENT DROPOUT AFTER INITIAL TREATMENT WITH 100 UNITS

45. MP83-01 ACCELERATING THE LEARNING CURVE: A NOVEL EXPERT COACHING MODEL IN UROLOGY

46. PD23-08 ENHANCED INTRAOPERATIVE NERVE VISUALIZATION: PROOF OF CONCEPT

47. MP55-17 IS UROTHELIAL CARCINOMA WITH SARCOMATOID DIFFERENTIATION RESPONSIVE TO NEOADJUVANT CHEMOTHERAPY?

48. PD55-01 A PROSPECTIVE SINGLE-BLINDED RANDOMIZED CONTROLLED CLINICAL TRIAL OF PERIOPERATIVE GOAL-DIRECTED FLUID THERAPY VERSUS STANDARD FLUID THERAPY FOR PATIENTS UNDERGOING OPEN RADICAL CYSTECTOMY ON A STANDARDIZED POSTOPERATIVE ENHANCED RECOVERY PATHWAY

49. PD18-01 RADIOGRAPHIC PREDICTORS OF PATHOLOGIC RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH HIGH-GRADE UPPER TRACT UROTHELIAL CARCINOMA: RESULTS OF A PHASE 2 CLINICAL TRIAL

50. MP55-16 SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE-METASTATIC CARCINOMA OF THE BLADDER OR UPPER URINARY TRACT

Catalog

Books, media, physical & digital resources